<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="469">
  <stage>Registered</stage>
  <submitdate>8/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <actrnumber>ACTRN12605000380695</actrnumber>
  <trial_identification>
    <studytitle>Induction Of Mixed Haematopoietic Chimerism In Patients Using Fludarabine, Low Dose Total Body Irradiation, Peripheral Blood Stem Cell Infusion And Post-Transplant Immunosuppression With Cyclosporine And Mycophenolate Mofetil</studytitle>
    <scientifictitle>Evaluation of Donor/Recipient Chimerism and graft rejection in patients who have undergone a Peripheral Blood Stem Cell allograft following Fludarabine and Low dose Total Body Irradiation as a non-myeloablative conditioning regimen.</scientifictitle>
    <utrn />
    <trialacronym>Flu TBI</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Myelodysplastic syndromes.</healthcondition>
    <healthcondition>Myeloproliferative syndromes.</healthcondition>
    <healthcondition>Acute Leukemia with &lt; 10% blasts.</healthcondition>
    <healthcondition>Amyloidosis</healthcondition>
    <healthcondition>Hodgkins disease.</healthcondition>
    <healthcondition>Multiple Myeloma</healthcondition>
    <healthcondition>Non-Hodgkins lymphoma</healthcondition>
    <healthcondition>Chronic myeloid leukaemia</healthcondition>
    <healthcondition>Chronic lymphocytic leukaemia</healthcondition>
    <healthcondition>Renal cell carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Hodgkin's</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Myeloma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Renal Cell Carcinoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>It is planned to test the hypothesis that we can reliably establish mixed chimerism in humans using a non-myeloablative regimen and that we can decrease the incidence of graft rejection by the addition of 3 doses of fludarabine (30 mg/m2 given days -4, -3, -2) before 200 cGy TBI. Mixed chimerism will be defined as the detection of donor cells after transplant at &gt; than 1% and  &lt;= 95% of the eripheral blood CD3+ cell population.  Patients with low levels of T cell chimerism or those with continued evidence of malignancy (without GVHD) will be evaluated for the effects of DLI on conversion to full chimerism and for anti-tumour activity.  The source of stem cells will be G-CSF mobilised PBSC from apheresis products collected on two consecutive days infused into the patient on day 0. Donor lymphocyte infusions may be given starting 2 months post-transplant in an  attempt to convert mixed chimerism to full donor chimerism and to eradicate the malignancy.  A graded series of T cell doses will be employed to reduce the risks of severe GVHD. For unrelated donor transplants, Bone Marrow will be used a the stem cell source if PBSC is not available.</interventions>
    <comparator />
    <control>Historical</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To estimate the risk of graft rejection associated with the addition of fludarabine to a non-myeloablative conditioning regimen for patients with malignant diseases treatable by allogeneic stem cell transplantation and compare this rate to that observed among patients previously treated without fludarabine.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate the rate of grade acute II/IV GVHD and chronic GVHD in patients treated with low-dose TBI, Fludarabine, PBSC infusion and immunosuppression with Cyclosporine and Mycophenolate Mofetil.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with haematological malignancy or metastatic renal cancer who are not eligible for a curative autologous transplantation or who have failed prior autologous transplantation and are not suitable for ablative conditioning regimes due to a high risk of treatment related morbidity/mortality (eg age, prior autologous transplant, pre-existing medical conditions). Patients with NHL and CLL must have failed prior therapy with an alkylating agent and/or fludarabine, or be at high risk of relapse.  Patients with multiple myeloma must have stage II or III disease and received prior chemotherapy.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>19/01/2001</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof Durrant</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Brisbane and Women's Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bone Marrow Transplant Unit - Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bone Marrow and Stem Cell Transplant Unit - Royal Children's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Simon Durrant</name>
      <address>Bone Marrow Transplantation (BMT) Unit
Cancer Care Services
Royal Brisbane and Women's Hospital
Level 5 
Joyce Tweddell Building
Butterfield Street
Herston Brisbane QLD 4029</address>
      <phone>+61 7 36368111</phone>
      <fax />
      <email>Simon_Durrant@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mrs Robyn Western</name>
      <address>Cancer Care Clinical Trials
Bone Marrow Transplantation (BMT) Department
Royal Brisbane and Women's Hospital
Level 5
Joyce Tweddell Building
Butterfield Street
Herston Brisbane QLD 4029</address>
      <phone>+61 7 36365378</phone>
      <fax />
      <email>Robyn_Western@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>